Malaria vaccines in development

Expert Opinion on Emerging Drugs

Volumn 10, Issue 3, 2005, Pages 489-503

  Ballou, W Ripley ^a  

^a GSK   (Belgium)

Author keywords

Adjuvants; Asexual stages; Attenuated viral vectors; Blood stage; Clinical trials; Immunity; Malaria; Merozoite; Plasmodium falciparum; Pre erythrocytic; Recombinant proteins; Sporozoite; Vaccines

Indexed keywords

ADENOVIRUS 35 CS; DNA VACCINE; ICC 1132; LIVER STAGE ANTIGEN 1; MALARIA VACCINE; ME TRAP; MEROZOITE SURFACE PROTEIN 1; MODIFIED VACCINIA ANKARA; PLASMID DNA; PROTEIN AMA 1; PROTEIN AMA 1 C1; PROTEIN MSP 3; RTS S; SPOROZOITE VACCINE; SYNTHETIC PEPTIDE VACCINE; UNCLASSIFIED DRUG; VIROSOME VACCINE; VIRUS VECTOR;

CLINICAL TRIAL; DEVELOPING COUNTRY; ENDEMIC DISEASE; HUMAN; MALARIA; MALARIA CONTROL; NONHUMAN; PLASMODIUM FALCIPARUM; POPULATION; REVIEW; SPOROZOITE;

ANIMALS; CLINICAL TRIALS; DRUG INDUSTRY; HUMANS; MALARIA; MALARIA VACCINES; PLASMODIUM FALCIPARUM; WORLD HEALTH;

EID: 23844521983     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.10.3.489     Document Type: Review

References (112)

1. SNOW RW, GUERRA CA, NOOR AM et al.: The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature (2005) 434:214-217.
2. GARDNER MJ, HALL N, FUNG E et al.: Genome sequence of the human malaria parasite plasmodium falciparum. Nature (2002) 419:498-511.
3. BALLOU WR, KESTER KE, HEPPNER DG: Pre-erythrocytic malaria vaccines to prevent Plasmodium falciparum malaria. In: Malaria Immunology. P Perlmann, M Troye-Blomberg (Eds). Chem. Immunol. Basel, Karger, Switzerland (2002):253-261.
4. HOFFMAN SL, WISTAR R, BALLOU WR et al.: Immunity to malaria and naturally acquired antibodies to the circumsporozoite protein of Plasmodium falciparum. N. Engl. J. Med. (1986) 315:601-606.
5. PLEBANSKI M, AIDOO M, WHITTLE HC et al.: Precursor frequency analysis of cytotoxic T lymphocytes to pre-erythrocytic antigens of Plasmodium falciparum in west Africa. J. Immunol. (1997) 158:2849-2855.
6. SCHELLENBERG D, MENENDEZ C, KAHIGWA E et al.: African children with malaria in an area of intense Plasmodium falciparum transmission: features on admission to the hospital and risk factors for death. Am. J. Trop. Med. Hyg. (1999) 61:431-438.
7. THOMAS AW, TRAPE JF, ROGIER C, GONCALVES A, ROSARIO VE, NARUM DL: High prevalence of natural antibodies against Plasmodium falciparum 83-kilodalton apical membrane antigen (PF83/AMA-1) as detected by capture-enzyme-linked immunosorbent assay using full-length baculovirus recombinant PF83/AMA-1. Am. J. Trop. Med. Hyg. (1994) 51(6):730-740.
8. GOOD MF: Vaccine-induced immunity to malaria parasites and the need for novel strategies. Trends Parasitol. (2005) 21:29-34.
9. BLACKMAN MJ, SCOTT-FINNIGAN TJ, SHAI S, HOLDER AA: Antibodies inhibit the protease-mediated processing of a malaria merozoite surface protein. J. Exp. Med. (1994) 180:389-393.
10. SCHOFIELD L, HEWITT MC, EVANS K et al.: Synthetic GPI as a candidate anti-toxic vaccine in a model of malaria. Nature (2002) 418:785-789.
11. KASLOW DC: Transmission-blocking vaccines. Chem. Immunol. (2002) 80:287-307.
12. BALLOU WR, KESTER KE, STOUTE JA et al.: Malaria vaccines: triumphs or tribulations? Parasitologia (1999) 41(1-3):403-408.
13. NUSSENZWEIG RS, VANDERBERG J, MOST H, ORTON C: Protective immunity produced by the injection of X-irradiated sporozoites of Plasmodium berghei. Nature (1967) 216:160-162.
14. NUSSENZWEIG V, NUSSENZWEIG RS: Rationale for the development of an engineered sporozoite malaria vaccine. Adv. Immunol. (1989) 45:283-334.
15. CLYDE DF, MOST H, MCCARTHY VC, VANDERBERG JP: Immunization of man against sporozite-induced falciparum malaria. Am. J. Med. Sci. (1973) 266:169-177.
16. EGAN JE, WEBER JL, BALLOU WR et al.: Efficacy of murine malaria sporozoite vaccines: implications for human vaccine development. Science (1987) 236:453-456.
17. NARDIN EH, NUSSENZWEIG RS, ALTSZULER R et al.: Cellular and humoral immune responses to a recombinant P. falciparum CS protein in sporozoite-immunized rodents and human volunteers. Bull. World Health Organ. (1990) 68:85-87.
18. EGAN JE, HOFFMAN SL, HAYNES JD et al.: Humoral immune responses in volunteers immunized with irradiated Plasmodium falciparum sporozoites. Am. J. Trop. Med. Hyg. (1993) 49:166-173.
19. KRZYCH U, LYON JL, JAREED T et al.: T lymphocytes from volunteers immunized with irradiated P. falciparum sporozoites recognize liver and blood stage malaria antigens. J. Immunol. (1995) 155:4072-4077.
20. HOFFMAN SL, GOH LM, LUKE TC et al.: Protection of humans against malaria by immunization with radiation attenuated Plasmodium species sporozoites. J. Infect. Dis. (2002) 185:1155-1164.
21. BEIER JC, BEIER MS, VAUGHAN JA, PUMPUNI CB, DAVIS JR, NODEN BH: Sporozoite transmission by Anopheles freeborni and Anopheles gambiae experimentally infected with Plasmodium falciparum. J. Am. Mosq. Control Assoc. (1992) 8:404-408.
22. SCHELLER LF, AZAD AF: Maintenance of protective immunity against malaria by persistent hepatic parasites derived from irradiated sporozoites. Proc. Natl. Acad. Sci. USA (1995) 92:4066-4068.
23. BEJON P, ANDREWS L, ANDERSEN F et al.: Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites. J. Infect. Dis. (2005) 191:619-626.
24. BROWN AE, SINGHARAJ P, WEBSTER HK et al.: Safety, immunogenicity and limited efficacy study of a recombinant Plasmodium falciparum circumsporozoite vaccine in Thai soldiers. Vaccine (1994) 12:102-108.
25. SHERWOOD JA, COPELAND RS, TAYLOR KA et al.: Plasmodium falciparum circumsporozoite vaccine immunogencity and efficacy trial with natural challenge quantitation in an area of endemic human malaria of Kenya. Vaccine (1996) 14:817-827.
26. MOORTHY VS, IMOUKHUEDE EB, MILLIGAN P et al.: A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults. PLoS Med. (2004) 1:128-136.
27. KESTER KE, MCKINNEY DA, TORNIEPORTH N et al.: Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. J. Inf. Dis. (2001) 183:640-647.
28. ALONSO PL, SACARLAL J, APONTE JJ et al.: Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet (2004) 364:1411-1420.
29. SCHELLENBERG D, MENENDEZ C, KAHIGWA E et al.: Intermittent treatment for malaria and anaemia control at time of routine vaccination in Tanzanian infants; a randomised, placebo-controlled trial. Lancet (2001) 357:1471-1477.
30. MASSAGA JJ, KITUA AY, LEMNGE M et al.: Effect of intermittent treatment with amodiaquine on anaemia and malaria fevers in Tanzania; a randomised, placebo-controlled trial. Lancet (2003) 361:1853-1860.
31. LENGELER C: Insecticide-treated bed nets and curtains for preventing malaria. Cochrane Database Syst. Rev. (2004) 2:CD000363.
32. BALLOU WR, ROTHBARD J, WIRTZ RA et al.: Immunogenicity of synthetic peptides from the circumsporozoite protein of Plasmodium falciparum. Science (1985) 228:996-999.
33. RATHORE D, NAGARKATTII R, JANI D et al.: An immunologically cryptic epitope of Plasmodium falciparum circumsporozoite protein facilitates liver cell recognition and induces protective antibodies that block liver cell invasion. J. Biol. Chem. (2005) 280(21):20524-20529.
34. REECE WH, PINDER M, GOTHARD PK et al.: A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease. Nat. Med. (2004) 10:406-410.
35. + T cells. J. Immunol. (2003) 171:2024-2034.
36. CHULAY, JD, SCHNEIDER I, COSGRIFF TM et al.: Malaria transmitted to man by mosquitoes infected from cultured Plasmodium falciparum. Am. Soc. Trop. Med. Hyg. (1986) 35:66-68.
37. STOUTE JA., SLAOUI M, HEPPNER DG et al.: A preliminary evaluation of a recombinant circumsporozoite protein malaria vaccine against Plasmodium falciparum. N. Engl. J. Med. (1997) 336:86-91.
38. BENMOHAMED L, THOMAS A, DRUILHE P: Long-term multiepitopic cytotoxic-T-lymphocyte responses induced in chimpanzees by combinations of Plasmodium falciparum liver-stage peptides and lipopeptides. Infect. Immun. (2004) 72:4376-4384.
39. VUOLA JM, KEATING S, WEBSTER DP et al.: Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers. J. Immunol. (2005) 174:449-455.
40. GORDON DM, MCGOVERN TW, KRZYCH U et al.: Safety, immunogenicity and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein/HBsAg subunit vaccine. J. Inf. Dis. (1995) 171:1576-1585.
41. GARCON N, HEPPNER DG, COHEN J: Development of RTS,S/AS02: a purified subunit-based malaria vaccine candidate formulated with a novel adjuvant. Expert Rev. Vaccines (2003) 2:231-238.
42. +) T cells producing IFN-gamma. J. Immunol. (2003) 171(12):6961-6967.
43. LALVANI A, MORIS P, VOSS G et al.: Potent induction of focused Th-1 type cellular and humoral immune responses by RTS,S/SBAS2 recombinant P. falciparum malaria vaccine. J. Infect. Dis. (1999) 180:1656-1664.
44. STOUTE, JA, KESTER KE, KRZYCH U et al.: Long term efficacy and immune responses following immunization with the RTS,S malaria vaccine. J. Infect. Dis. (1998) 178:1139-1144.
45. DOHERTY JF, PINDER M, TORNIEPORTH N et al.: A Phase I safety and immunogenicity trial with the candidate malaria vaccine, RTS,S/SABAS2, in semi-immune adults in the Gambia. Am. J. Trop. Med. Hyg. (1999) 61:865-868.
46. PINDER M, REECE WH, PLEBANSKI M et al.: Cellular immunity induced by the recombinant Plasmodium falciparum malaria vaccine, RTS,S/AS02, in semi-immune adults in the Gambia. Clin. Exp. Immunol. (2004) 135:286-293.
47. BOJANG KA, MILLIGAN PJ, PINDER M et al.: Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in the Gambia: a randomised trial. Lancet (2001) 358:1927-1934.
48. HEPPNER DG, CUMMINGS JF, OCKENHOUSE CF, KESTER KE, COHEN JD, BALLOU WR: Adjuvanted RTS,S and other protein-based preerythrocytic stage malaria vaccines. In: New Generation Vaccines, 3rd Ed. MM Levine, JB Kaper, R Rappuoli, MA Liu, MF Good (Eds), Dekker, New York, USA (2004):851-860.
49. HEPPNER DG Jr, KESTER KE, OCKENHOUSE CF et al.: Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. Vaccine (2005) 23:2243-2250.
50. BIRKETT A, LYONS K, SCHMIDT A et al.: A modified hepatitis B virus core particle containing multiple epitopes of the Plasmodium falciparum circumsporozoite protein provides a highly immunogenic malaria vaccine in preclinical analyses in rodent and primate hosts. Infect. Immun. (2002) 70(12):6860-6870.
51. MILICH DR, HUGHES J, JONES J, SALLBERG M, PHILLIPS TR: Conversion of poorly immunogenic malaria repeat sequences into a highly immunogenic vaccine candidate. Vaccine (2002) 20:771-778.
52. NARDIN EH, OLIVEIRA GA, CALVO-CALLE JM et al.: Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes. Infect. Immun. (2004) 72(11):6519-6527.
53. WALTHER M, DUNACHIE S, KEATING S et al.: Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720. Vaccine (2005) 23(7):857-864.
54. + T cell immune responses and protection elicited against Plasmodium berghei malaria by prime boost immunization regimens using a novel attenuated fowlpox virus. J. Immunol. (2004) 172:3094-3100.
55. MOORE AC, HILL AV: Progress in DNA-based heterologous prime-boost immunization strategies for malaria. Immunol. Rev. (2004) 199:126-143.
56. WEBSTER DP, DUNACHIE S, VUOLA JM et al.: Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc. Natl. Acad. Sci. USA (2005) 102:4836-4841.
57. MOORTHY VS, MCCONKEY S, ROBERTS M et al.: Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. Vaccine (2003) 21:2004-2011.
58. MCCONKEY SJ, MOORTHY V, WEBSTER D et al.: Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat. Med. (2003) 9:729-735.
59. BRUNA-ROMERO O, GONZALEZ-ASEGUINOLAZA G, HAFALLA JC, TSUJI M, NUSSENZWEIG RS: Complete, long-lasting protection against malaria of mice primed and boosted with two distinct viral vectors expressing the same plasmodial antigen. Proc. Natl. Acad. Sci. USA (2001) 98:11491-11496.
60. BAROUCH DH, PAU MG, CUSTERS JH et al.: Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J. Immunol. (2004) 172(10):6290-6297.
61. ROGGERO MA, WEILENMANN C, BONELO A et al.: Plasmodium falciparum CS C-terminal fragment: preclinical evaluation and Phase I clinical studies. Parasitologia (1999) 41:421-424.
62. + T lymphocyte immune response in humans. Implications for vaccination strategies. Eur. J. Immunol. (2001) 31:1989-1998.
63. PRATO S, MAXWELL T, PINZ A et al.: MHC class I-restricted exogenous presentation of a synthetic 102-mer malaria vaccine polypeptide. Eur. J. Immunol. (2005) 35:681-689.
64. SMOOKER P, RAINCZUK A, KENNEDY N, SPITHILL T: DNA vaccines and their application against parasites - promise, limitations and potential solutions. Biotechnol. Ann. Rev. (2004) 10:189-236.
65. WANG R, DOOLAN DL, LE TP et al.: Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science (1998) 282:476-480.
66. +) Type 1 responses in humans by a malaria DNA vaccine. Proc. Natl. Acad. Sci. USA (2001) 98:10817-10822.
67. BALLOU WR, AREVELO-HERRERA M, CARUCCI D et al.: Update on the clinical development of candidate malaria vaccines. Am. J. Trop. Med. Hyg. (2004) 71:239-247.
68. KURTIS JD, HOLLINGDALE MR, LUTY AJ, LANAR DE, KRZYCH U, DUFFY PE: Pre-erythrocytic immunity to Plasmodium falciparum: the case for an LSA-1 vaccine. Trends Parasitol. (2001) 17:219-223.
69. HILLIER CJ, WARE LA, BARBOSA A et al.: Process development and analysis of liver-stage antigen 1, a preerythrocyte-stage protein-based vaccine for Plasmodium falciparum. Infect. Immun. (2005) 73:2109-2115.
70. DAUBERSIES P, THOMAS AW, MILLET P et al.: Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3. Nat. Med. (2000) 6:1258-1263.
71. PERLAZA BL, ZAPATA C, VALENCIA AZ et al.: Immunogenicity and protective efficacy of Plasmodium falciparum liver-stage Ag-3 in Aotus lemurinus griseimembra monkeys. Eur. J. Immunol. (2003) 33:1321-1327.
72. MORENO R, JIANG L, MOEHLE K et al.: Exploiting conformationally constrained peptidomimetics and an efficient human-compatible delivery system in synthetic vaccine design. Chembiochem. (2001) 5:838-843.
73. PFEIFFER B, PEDUZZI E, MOEHLE K et al.: A virosome-mimotope approach to synthetic vaccine design and optimization: synthesis, conformation, and immune recognition of a potential malaria-vaccine candidate. Angew. Chem. Int. Ed. Engl. (2003) 42(21):2368-2371.
74. MAHANTY S, SAUL A, MILLER LH: Progress in the development of recombinant and synthetic blood-stage malaria vaccines. J. Exp. Biol. (2003) 206:3781-3788.
75. GOOD MF, XU H, WYKES M, ENGWERDA CR: Development and regulation of cell-mediated immune responses to the blood stages of malaria: implications for vaccine research. Ann. Rev. Immunol. (2005) 23:69-99.
76. OEUVRAY C, BOUHAROUN-TAYOUN H, GRASMASSE H et al.: Merozoite surface protein-3: a malaria protein inducing antibodies that promote Plasmodium falciparum killing by cooperation with blood monocytes. Blood (1994) 84:1594-1602.
77. STRUIK SS, RILEY EM: Does malaria suffer from lack of memory? Immunol. Rev. (2004) 201:268-290.
78. DIGGS CL, BALLOU WR, MILLER LH et al.: The major merozoite surface protein as a malaria vaccine target. Parasitol. Today (1994) 9:300-302.
79. 33 as a noncovalently associated complex with other fragments of the MSP1. Mol. Biochem. Parasitol. (1992) 50:307-315.
80. CHITNIS CE, BLACKMAN MJ: Host cell invasion by malaria parasites. Parasitol. Today (2000) 10:411-415.
81. MILLER LH, ROBERTS T, SHAHABUDDIN M, MCCUTCHAN TF: Analysis of sequence diversity in the Plasmodium falciparum merozoite surface protein-1 (MSP-1). Mol. Biochem. Parasitol. (1993) 59:1-14.
82. MORGAN WD, BIRDSALL B, FRENKIEL TA et al.: Solution structure of an EGF module pair from the Plasmodium falciparum merozoite surface protein 1. J. Mol. Biol. (1999) 289:113-122.
83. GUEVARA-PATINO JA, HOLDER AA, MCBRIDE JS, BLACKMAN MJ: Antibodies that inhibit malaria merozoite surface protein-1 processing and erythrocyte invasion are blocked by naturally acquired human antibodies. J. Exp. Med. (1999) 186:1689-1699.
84. KUMAR S, YADAVA A, KEISTER DB et al.: Immunogenicity and in vivo efficacy of recombinant Plasmodium falciparum merozoite surface protein-1 in Aotus monkeys. Mol. Med. (1995) 1:332.
85. LEE EA, PALMER DR, FLANAGAN KL et al.: Induction of T helper Type 1 and 2 responses to 19-kilodalton merozoite surface protein 1 in vaccinated healthy volunteers and adults naturally exposed to malaria. Infect. Immun. (2002) 70(3):1417-1421.
86. ANGOV E, AUFERIO B, TURGEON A et al.: Development and pre-clinical analysis of a Plasmodium falciparum merozoite surface protein-142 malaria vaccine. Mol. Biochem. Parasitol. (2003) 128:195-204.
87. PICHYANGKUL S, GETTAYACAMIN M, MILLER S et al.: Pre-clinical evaluation of the malaria vaccine candidate P. falciparum MSP1-42 formulated with novel adjuvants or with alum. Vaccine (2004) 22:3831-3840.
88. DARKO CA, ANGOV E, COLLINS WE et al.: The clinical-grade 42-kilodalton fragment of merozoite surface protein 1 of Plasmodium falciparum strain FVO expressed in Escherichia coli protects Aotus nancymai against challenge with homologous erythrocytic-stage parasites. Infect. Immun. (2005) 73:287-297.
89. SINGH S, KENNEDY MC, LONG CA, SAUL AJ, MILLER LH, STOWERS AW: Biochemical and immunological characterization of bacterially expressed and refolded Plasmodium falciparum 42-kilodalton C-terminal merozoite surface protein 1. Infect. Immun. (2003) 71:6766-6774.
90. MILES AP, MCCLELLAN HC, RAUSCH KM et al.: Montanide® ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations. Vaccine (2005) 23:2528-2537.
91. PERRAUT R, MARRAMA L, DIOUF B et al.: Antibodies to the conserved C-terminal domain of the Plasmodium falciparum merozoite surface protein 1 and to the merozoite extract and their relationship with in vitro inhibitory antibodies and protection against clinical malaria in a Senegalese village. J. Infect. Dis. (2005) 191:264-271.
92. PERERA KL, HANDUNNETTI SM, HOLM I, LONGACRE S, MENDIS K: Baculovirus merozoite surface protein 1 C-terminal recombinant antigens are highly protective in a natural primate model for human Plasmodium vivax malaria. Infect. Immun. (1998) 66:1500-1506.
93. 19) and T-helper epitopes of tetanus toxoid. Vaccine (1999) 18:531-539.
94. MILLER LH, BARUCH BI, MARSH K, DOUMBO OK: The pathogenic basis of malaria. Nature (2002) 415:673-679.
95. POLLEY SD, MWANGI T, KOCKEN CH et al.: Human antibodies to recombinant protein constructs of Plasmodium falciparum apical membrane antigen 1 (AMA1) and their associations with protection from malaria. Vaccine (2004) 23:718-728.
96. NARUM DL, THOMAS AW: Differential localization of full-length and processed forms of PF83/AMA-1, an apical membrane antigen of Plasmodium falciparum merozoites. Mol. Biochem. Parasitol. (1984) 67:59-68.
97. BANNISTER LH, HOPKINS JM, DLUZEWSKI AR et al.: Plasmodium falciparum apical membrane antigen 1 (PfAMA-1) is translocated within micronemes along subpellicular microtubules during merozoite development. J. Cell Sci. (2003) 116:3825-3834.
98. SILVIE O, FRANETICH JF, CHARRIN S et al.: A role for apical membrane antigen 1 during invasion of hepatocytes by Plasmodium falciparum sporozoites. J. Biol. Chem. (2004) 279:9490-9496.
99. PIZARRO JC, VULLIEZ-LE NORMAND B, CHESNE-SECK ML et al.: Crystal structure of the malaria vaccine candidate apical membrane antigen 1. Science (2005) 308(5720):408-411.
100. DUTTA S, HAYNES JD, BARBOSA A et al.: Mode of action of invasion-inhibitory antibodies directed against apical membrane antigen 1 of Plasmodium falciparum. Infect. Immun. (2005) 73:2116-2122.
101. CORTE A, MELLOMBO M, MASCIANTONIO R et al.: Allele specificity of naturally acquired antibody responses against Plasmodium falciparum apical membrane antigen 1. Infect. Immun. (2005) 73:422-430.
102. DUTTA S, LALITHA PV, WARE LA et al.: Purification, characterization, and immunogenicity of the refolded ectodomain of the Plasmodium falciparum apical membrane antigen 1 expressed in Escherichia coli. Infect. Immun. (2002) 70:3101-3110.
103. LALITHA PV, WARE LA, BARBOSA A et al.: Production of the subdomains of the Plasmodium falciparum apical membrane antigen 1 ectodomain and analysis of the immune response. Infect. Immun. (2004) 72:4464-4470.
104. KENNEDY M, WANG J, ZHANG Y et al.: In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response. Infect. Immun. (2002) 70:6948-6960.
105. STOWERS AW, KENNEDY MC, KEEGAN BP, SAUL A, LONG CA, MILLER LH: Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malaria. Infect. Immun. (2002) 70:6961-6967.
106. VULLIEZ-LE NORMAND B, PIZARRO JC, CHESNE-SECK ML et al.: Expression, crystallization and preliminary structural analysis of the ectoplasmic region of apical membrane antigen 1 from Plasmodium vivax, a malaria-vaccine candidate. Acta Crystallogr. D. Biol. Crystallogr. (2004) 60:2040-2043.
107. KOCKEN C, WITHERS-MARTINEZ C, DUBBELD M et al.: High-level expression of the malaria blood-stage vaccine candidate Plasmodium falciparum apical membrane antigen 1 and induction of antibodies that inhibit erythrocyte invasion. Infect. Immun. (2002) 70:4471-4476.
108. PAN W, HUANG D, ZHANG Q et al.: Fusion of two malaria vaccine candidate antigens enhances product yield, immunogenicity, and antibody-mediated inhibition of parasite growth in vitro. J. Immunol. (2004) 172:6167-6174.
109. MUELLER MS, RENARD A, BOATO F et al.: Induction of parasite growth-inhibitory antibodies by a virosomal formulation of a peptidomimetic of loop I from domain III of Plasmodium falciparum apical membrane antigen 1. Infect. Immun. (2003) 71:4749-4758.
110. THEISEN M, SOE S, BRUNSTEDT K et al.: A Plasmodium falciparum GLURP-MSP3 chimeric protein; expression in Lactococcus lactis, immunogenicity and induction of biologically active antibodies. Vaccine (2004) 22:1188-1198.
111. LUKE TC, HOFFMAN: Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuated Plasmodium falciparum sporozoite vaccine. J. Exp. Biol. (2003) 206:3803-3808.
112. HURD H, AL-OLAYAN E, BUTCHER GA et al.: In vitro methods for culturing vertebrate and mosquito stages of Plasmodium. Microbes Infect. (2003) 5:321-327.